Tularemia News and Research

RSS
Tularemia is a disease of animals and humans caused by the bacterium Francisella tularensis. Rabbits, hares, and rodents are especially susceptible and often die in large numbers during outbreaks. Humans can become infected through several routes, including tick and deer fly bites, skin contact with infected animals, ingestion of contaminated water, or inhalation of contaminated dusts or aerosols. In addition, humans could be exposed as a result of bioterrorism. Symptoms vary depending upon the route of infection. Although tularemia can be life-threatening, most infections can be treated successfully with antibiotics. Steps to prevent tularemia include use of insect repellent, wearing gloves when handling sick or dead animals, and not mowing over dead animals. In the United States, naturally occurring infections have been reported from all States except Hawaii.
FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Mimicry allows bacteria to evade host's defense responses

Mimicry allows bacteria to evade host's defense responses

UIC receives federal contract to develop antibiotics against three bacterial infections

UIC receives federal contract to develop antibiotics against three bacterial infections

Aduro raises $19.25 million through Series B equity financing

Aduro raises $19.25 million through Series B equity financing

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm fourth quarter revenue is $144,000 for 2010

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study

Aradigm reports positive data from DRCFI, ARD-3150 Phase 2b bronchiectasis study